VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRMDIRadimed Corporation
$82.31$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRMDBalance Sheet

IRadimed Corporation (IRMD) Balance Sheet

14Y historyFree accessUpdated daily

IRMD carries no reported debt and holds a current ratio near 9.0 with equity of $106.5M against $14.6M in liabilities, suggesting minimal refinancing risk, though a large cash share of assets may flatter headline asset growth.

Income StatementBalance SheetCash FlowRatios

IRMD Balance Sheet

Annual statement

IRMD Balance Sheet

IRadimed Corporation (IRMD) balance sheet — 14-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total Current Assets92.8M81.2M75.24M76M77.49M76.24M63.74M58.96M44.54M35.11M34.17M33.95M22.17M6.38M5M
Cash & Short-Term Investments63.29M51.16M52.23M49.76M57.96M62.5M51.98M46.25M34.38M26.34M25.68M26.97M17.37M2.71M1.95M
Cash Only63.29M51.16M52.23M49.76M57.96M62M50.07M43.48M28.03M18.21M17.71M19.37M9.45M2.46M1.7M
Short-Term Investments00000501.86K1.91M2.77M6.35M8.14M7.97M7.6M7.91M246.2K250.79K
Accounts Receivable13.67M13.67M10.56M12.22M13.27M5.14M4.57M7.29M4.21M3.78M3.78M3.86M1.96M1.98M1.59M
Days Sales Outstanding55.159.5252.6168.0690.944.8452.6569.1150.4859.7642.4144.6445.7163.875.3
Inventory011.62M10.4M12.82M5.37M4.3M3.93M3.64M4.06M4.21M3.89M2.38M2.13M1.34M1.39M
Days Inventory Outstanding149.15217.61224.76303.8163.03160.73176.34150.77205.46275.94230.49148.94227.92171.45237.96
Other Current Assets15.84M4.76M2.05M1.19M630.96K1M771.67K407.8K526.79K648.88K674.77K459.4K392.88K183.6K77.22K
Total Non-Current Assets28.27M27.57M23.08M16.15M8.02M6.64M7.33M7.77M3.9M3.9M3.03M1.29M1.14M602.6K557.41K
Property, Plant & Equipment24.08M23.86M16.97M11.33M4.61M4.55M4.84M5.01M1.87M1.87M1.46M905.62K794.84K327.34K265.62K
Fixed Asset Turnover3.71x3.51x4.32x5.79x11.57x9.19x6.56x7.69x16.28x12.35x22.32x34.89x19.69x34.64x28.93x
Goodwill000000000000000
Intangible Assets3.41M3.38M3.1M2.52M2.07M1.12M960.88K860.09K832.52K885.5K918.71K175.51K250.84K267.02K276.03K
Long-Term Investments000000000000000
Other Non-Current Assets782K239K198.91K181.45K648.67K201.32K261.99K232K109.76K200.2K173.82K124.19K19.68K8.23K3.24K
Total Assets121.07M108.78M98.33M92.16M85.51M82.88M71.07M66.73M48.44M39.01M37.19M35.24M23.31M6.99M5.55M
Asset Turnover0.78x0.77x0.74x0.71x0.62x0.50x0.45x0.58x0.63x0.59x0.87x0.90x0.67x1.62x1.38x
Asset Growth %36.62%10.63%6.69%7.77%3.18%16.63%6.5%37.75%24.17%4.89%5.53%51.2%233.62%25.79%-
Total Current Liabilities10.32M10.18M8.51M16.33M8.55M6.82M4.92M5.86M4.69M4.08M3.66M2.9M2.28M1.45M2.33M
Accounts Payable2.42M1.82M1.9M1.86M1.8M782.9K657.05K993.74K772.47K656.72K1.12M1.01M629.17K427.47K408.42K
Days Payables Outstanding34.4934.0840.984454.6329.2629.4541.1439.143.0466.4762.8467.4654.6870.12
Short-Term Debt00000000000006.33K519.73K
Deferred Revenue (Current)13.31M2.87M2.26M2.57M3.37M2.55M1.95M1.67M1.8M1.62M1.03M536.92K308.34K207.4K389.4K
Other Current Liabilities3.78M457K268.27K367.46K94.03K255.31K236.49K190.18K315.94K278.61K280.63K64.77K93.72K12K64.94K
Current Ratio8.99x7.98x8.84x4.65x9.06x11.18x12.96x10.06x9.50x8.61x9.33x11.73x9.74x4.40x2.14x
Quick Ratio8.99x6.84x7.62x3.87x8.43x10.54x12.16x9.44x8.63x7.58x8.27x10.90x8.81x3.47x1.55x
Cash Conversion Cycle169.76243.05236.39327.85199.3176.3199.53178.74216.85292.66206.43130.74206.17180.57243.14
Total Non-Current Liabilities4.29M3.98M2.99M4.41M3.29M3.88M4.76M5.35M1.81M2M1.64M415.78K142.9K111.76K2.66K
Long-Term Debt000000000000000
Capital Lease Obligations001.42K1.62M1.91M2.21M2.46M2.72M0000000
Deferred Tax Liabilities00000000000374.25K054.09K0
Other Non-Current Liabilities000000000000000
Total Liabilities14.62M14.16M11.51M20.74M11.84M10.71M9.68M11.2M6.5M6.08M5.31M3.31M2.42M1.56M2.33M
Total Debt00154.69K2.04M2.21M2.48M2.72M2.96M000006.33K519.73K
Net Debt-63.29M-51.16M-52.08M-47.72M-55.76M-59.52M-47.35M-40.53M-28.03M-18.21M-17.71M-19.37M-9.45M-2.46M-1.18M
Debt / Equity0.00x-0.00x0.03x0.03x0.03x0.04x0.05x-----0.00x0.16x
Debt / EBITDA0.00x-0.01x0.10x0.14x0.22x4.66x0.30x-----0.00x0.34x
Net Debt / EBITDA-2.07x-1.87x-2.29x-2.29x-3.42x-5.30x-81.26x-4.10x-3.94x-7.02x-1.59x-1.65x-2.94x-0.84x-0.77x
Interest Coverage---------------
Total Equity106.45M94.62M86.82M71.42M73.67M72.17M61.38M55.52M41.95M32.93M31.89M31.93M20.89M5.42M3.22M
Equity Growth %34.51%8.98%21.56%-3.06%2.08%17.58%10.55%32.37%27.38%3.27%-0.14%52.86%285.24%68.4%-
Book Value per Share8.277.366.795.615.835.734.934.523.462.812.662.542.040.520.31
Total Shareholders' Equity106.45M94.62M86.82M71.42M73.67M72.17M61.38M55.52M41.95M32.93M31.89M31.93M20.89M5.42M3.22M
Common Stock1K1K1.27K1.26K1.26K1.25K1.23K1.18K1.1K1.06K1.07K1.12K1.08K700700
Retained Earnings74.1M64.23M56.79M43.26M47.26M46.99M37.67M36.3M26.67M20.36M19.87M12.66M5.13M3.07M1.14M
Treasury Stock000000000000000
Accumulated OCI0000017.01K37.09K30.37K-42.19K-48.91K-36.85K-55.28K-21.47K9247.15K
Minority Interest000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Quarterly earnings volatility under launch

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Compounding Through Retained Earnings

Based on reported figures, IRMD's total equity expanded from $79.7M in Q2 2024 to $106.5M in Q3 2026, with retained earnings rising from $50.4M to $74.1M, indicating self-funded balance sheet strengthening over the period.

The steady climb in retained earnings, which accounts for most of the equity increase, suggests the business is internally funding its growth rather than relying on external capital. The quarter-over-quarter pattern is consistent rather than lumpy, which points to durable earnings generation instead of one-time gains. Investors should note that total assets grew at a similar pace, so the strengthening reflects accumulation of liquid resources rather than a balance sheet inflated by intangibles.

Cash Reserves Dominate Asset Base

As reported in financial statements, IRMD held $63.3M in cash in Q3 2026 against total liabilities of $14.6M, with the current ratio at 8.99, suggesting liquidity far exceeds near-term obligations.

A current ratio near 9 indicates the company could cover short-term liabilities many times over, which may provide substantial buffer against revenue shocks such as the Q2 2026 EPS miss. Cash has risen from $48.5M to $63.3M over the ten quarters, which appears to reflect retained cash flow rather than financing activity. The scale of idle liquidity may warrant monitoring for how management intends to deploy it, since large cash balances can dilute returns on equity.

Debt-Free Structure Limits Refinancing Exposure

According to recent SEC filings, IRMD's total debt declined from $371.8K in Q2 2024 to nil by Q3 2026, leaving a debt-to-equity ratio of effectively zero over the most recent quarters.

The complete retirement of borrowings suggests the company no longer carries refinancing or interest-rate risk, which removes a common source of balance sheet fragility in small-cap medical device companies. This structure implies that cash flow durability is not being partially committed to debt service. The conservative posture may also reflect limited need for external capital, which is consistent with the self-funded equity growth observed.

Deferred Revenue Tracks Service Contract Growth

Based on the supplied figures, deferred revenue rose from $5.3M in Q4 2024 to $7.9M in Q3 2026, a gain of roughly 49%, which may indicate growing recurring or service-linked obligations ahead of revenue recognition.

Deferred revenue growing faster than the broader revenue base could signal a rising share of prepaid service or extended warranty contracts, supporting the recurring-revenue thesis. However, the sequential movement is modest in absolute terms, so this should be read as a directional indicator rather than a strong forward guarantee. Investors should monitor whether deferred revenue continues to outpace reported revenue growth.

Goodwill-Free Assets Mask Asset Quality Questions

Based on reported figures, IRMD's net PP&E of $24.1M against total assets of $121.1M implies that a large share of the asset base is cash, which may make headline asset growth look stronger than the operating asset base warrants.

Because cash constitutes the majority of total assets, the reported asset expansion primarily reflects accumulated liquidity rather than productive capacity, which could flatter headline return-on-assets metrics. The absence of goodwill removes impairment risk, but it also means the company has not pursued acquisitions to broaden its platform. Investors should weigh whether the high cash share reflects disciplined capital management or limited reinvestment opportunities.

IRMD — Frequently Asked Questions

Quick answers to the most common questions about buying IRMD stock.

What are the total assets of IRadimed Corporation (IRMD)?

As of 2025, IRadimed Corporation (IRMD) had total assets of $108.8M including $81.2M in current assets.

How much debt does IRadimed Corporation (IRMD) have?

IRadimed Corporation (IRMD) carries total debt of $0.0M, offset by $51.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of IRadimed Corporation?

IRadimed Corporation (IRMD) has total shareholders' equity (book value) of $94.6M ($7.36 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is IRadimed Corporation's current ratio and liquidity?

IRadimed Corporation (IRMD) reported a current ratio of 7.98x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.